Advertisement
UK markets close in 4 hours 35 minutes
  • FTSE 100

    8,083.11
    +38.30 (+0.48%)
     
  • FTSE 250

    19,797.20
    -2.52 (-0.01%)
     
  • AIM

    755.00
    +0.13 (+0.02%)
     
  • GBP/EUR

    1.1633
    +0.0005 (+0.04%)
     
  • GBP/USD

    1.2435
    -0.0017 (-0.14%)
     
  • Bitcoin GBP

    53,414.54
    +118.40 (+0.22%)
     
  • CMC Crypto 200

    1,433.46
    +9.36 (+0.66%)
     
  • S&P 500

    5,070.55
    +59.95 (+1.20%)
     
  • DOW

    38,503.69
    +263.71 (+0.69%)
     
  • CRUDE OIL

    82.81
    -0.55 (-0.66%)
     
  • GOLD FUTURES

    2,328.10
    -14.00 (-0.60%)
     
  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     
  • HANG SENG

    17,201.27
    +372.34 (+2.21%)
     
  • DAX

    18,184.63
    +46.98 (+0.26%)
     
  • CAC 40

    8,134.11
    +28.33 (+0.35%)
     

Zacks.com featured highlights include Everest Re Group, Thermo Fisher Scientific and Sony Group

For Immediate Release

Chicago, IL – February 22, 2023 – Stocks in this week’s article are Everest Re Group, Ltd. RE, Thermo Fisher Scientific Inc. TMO and Sony Group Corp. SONY.

3 Stocks with Sales Growth to Buy Amid Persistent Inflation

Though the effectiveness of the Federal Reserve's ultra-aggressive monetary tightening is being witnessed, inflation is turning out to be "sticky." Hence, the central bank is likely to raise interest rates in the near term.

This has made investors wary about entering the stock market, as higher rates will likely lead to a recession/economic slowdown in 2023. Hence, a conventional stock-picking strategy is the need of the hour. One such way is selecting stocks with steady sales growth. In this regard, stocks like Everest Re Group, Ltd., Thermo Fisher Scientific Inc. and Sony Group Corp. are worth considering.

ADVERTISEMENT

While assessing any company, revenues are often more scrutinized than earnings. This is because investors want to make sure that a business has the capability of generating more sales over time to cater to an increasing customer base. Steady or declining sales growth reflects obstacles at the company. Stagnant companies may generate profit in the near term but do not ensure enough growth to attract new investors.

Without robust revenue growth, bottom-line improvement may not be sustainable. While a company can show earnings strength by lowering costs, continued bottom-line expansion usually requires strong sales growth.

Nonetheless, sales growth alone doesn't show much about a company's prospects. So, taking into account a company's cash position along with its sales number can be a practical investment strategy. Substantial cash in hand and a steady cash flow give a company more flexibility with respect to business decisions and potential investments.

Here are three of the 16 stocks that qualified the screening:

Bermuda-based Everest Re writes property and casualty, reinsurance and insurance in the United States, Bermuda and international markets. RE also offers other innovative products like excess and surplus lines of insurance.

Everest Re's expected sales growth rate for 2023 is 13.1%. The stock sports a Zacks Rank #1 at present.

Headquartered in Waltham, MA, Thermo Fisher is a scientific instrument maker and a world leader in serving science. TMO operates through four segments – Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics and Laboratory Products and Biopharma Services.

Thermo Fisher's expected sales growth rate for 2023 is 1%. The stock currently carries a Zacks Rank #2.

Headquartered in Tokyo, Japan, Sony Group designs, manufactures and sells several consumer and industrial electronic equipment. SONY is also active in the production, acquisition and distribution of motion pictures as well as television programming, along with the operation of television and digital networks.

Sony Group's sales are expected to rise 8.3% in fiscal 2024. The stock sports a Zacks Rank #1 at present.

Get the rest of the stocks on the list and start putting this and other ideas to the test. It can all be done with the Research Wizard stock picking and backtesting software.

The Research Wizard is a great place to begin. It's easy to use. Everything is in plain language. And it's very intuitive. Start your Research Wizard trial today. And the next time you read an economic report, open up the Research Wizard, plug your finds in, and see what gems come out.

Click here to sign up for a free trial to the Research Wizard today.

For the rest of this Screen of the Week article please visit Zacks.com at: https://www.zacks.com/stock/news/2056638/3-stocks-with-sales-growth-to-buy-amid-persistent-inflation

Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material.

About Screen of the Week

Zacks.com created the first and best screening system on the web earning the distinction as the "#1 site for screening stocks" by Money Magazine.  But powerful screening tools is just the start. That is why Zacks created the Screen of the Week to highlight profitable stock picking strategies that investors can actively use.

Strong Stocks that Should Be in the News

Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has more than doubled the market from 1988 through 2016. Its average gain has been a stellar +25% per year. See these high-potential stocks free >>.

Follow us on Twitter:  https://www.twitter.com/zacksresearch

Join us on Facebook:  https://www.facebook.com/ZacksInvestmentResearch

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Contact: Jim Giaquinto

Company: Zacks.com

Phone: 312-265-9268

Email: pr@zacks.com

Visit: https://www.zacks.com/

Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. www.zacks.com/disclaimer.

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performancefor information about the performance numbers displayed in this press release.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Thermo Fisher Scientific Inc. (TMO) : Free Stock Analysis Report

Everest Re Group, Ltd. (RE) : Free Stock Analysis Report

Sony Corporation (SONY) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research